Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system

• US 4,898,732 A
• Filed: 05/04/1988
• Issued: 02/06/1990
• Est. Priority Date: 05/04/1988
• Status: Expired due to Fees

• Current Assignee: Clinipad Corp.
• Original Assignee: Clinipad Corp.
• Inventors: Fernandez, Leonardo A.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Horne, Leon R.
• Application Number:
  US07/190,158
• Time in Patent Office: 643 Days
• Field of Search: 514/16, 514/17, 424/427, 424/428
• US Class Current: 424/422
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• CPC Class Codes: A61K 38/553 Renin inhibitors
• CPC Class Codes: A61K 38/556 Angiotensin converting enzyme inhibitors
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L

Abstract

A method of inhibiting tumor growth in a patient which comprises administering to the patient an effective dose of a pharmaceutical antagonist of the renin-angiotensin system of the patient.

Claims

1. The method of implanting in a patient a controlled-release member, said member containing and releasing in controlled manner an effective dose a member selected from the group consisting of enalapril maleate, catapril and seralasin acetate, of a pharmaceutical antagonist of the renin-angiotensin system of said patient, whereby the growth of vascularization in said patient at least in an area adjacent said implanted controlled-release member is inhibited.

2. The method of claim 1, in which said controlled-release member is implanted at a tumor site.

3. The method of claim 2 in which said pharmaceutical antagonist is saralasin acetate.

4. The method of claim 2 in which said pharmaceutical antagonist is an antagonist to the action of angiotensin II.

5. The method of claim 2 in which said pharmaceutical antagonist inhibits the conversion of angiotensin I to angiotensin II.

6. The method or claim 2 in which said pharmaceutical antagonist is enalapril maleate.

7. The method of claim 2 in which said pharmaceutical antagonist is captopril.